In this video, Austin Smith interviews Jim Mueller, author of the Fool's premium report on Express Scripts. Jim thinks the company is a buy for three reasons:

  • $290 billion of drugs are coming off-patent over the next five years, and the company can benefit from selling more profitable generics.
  • The U.S. and European populations are aging. 
  • Obamacare will bring many more people onto the rolls.

For more details, check out the video.